Executive summary. Terpenes are volatile aromatic compounds found widely in plants, including cannabis. They contribute to aroma and may help characterise cultivars and products. They are also among the most overinterpreted constituents in cannabis marketing. A measured terpene profile is not equivalent to evidence of a clinical effect.
What terpenes are
Terpenes are built from isoprene units and include monoterpenes, sesquiterpenes and related oxygenated compounds. Common cannabis terpenes include myrcene, limonene, alpha-pinene, beta-caryophyllene and linalool. Their concentration varies with genetics, cultivation, harvest, drying and storage.
Because terpene concentrations shift with plant maturity, curing time and post-harvest handling, a terpene specification set from a single reference batch will not hold across a commercial cultivation programme without ongoing verification.
Volatility and processing
Terpenes can be lost during drying, milling, extraction, concentration and open handling. Heat and oxygen can change the profile. A process that preserves cannabinoids may still alter volatile constituents.
Volatility losses during decarboxylation and extraction mean the terpene profile of a finished extract can differ substantially from the starting flower — this should be characterised experimentally for each process rather than assumed to be proportional.
Analytical testing
Headspace GC-FID or GC-MS is commonly used. Sample preparation should minimise evaporation. Identity may rely on retention time, retention index, mass spectra and authentic standards. Library matching alone can misidentify related compounds.
GC-MS and GC-FID methods used for terpene quantification should be validated against the specific matrix being tested; a method validated for dried flower is not automatically fit for an oil-based finished product without re-verification.
Stability and packaging
Packaging permeability, headspace, closure integrity and repeated opening can reduce terpene content. Stability studies should control sample handling and distinguish true product loss from analytical variability.
Terpene-rich formulations require packaging and storage conditions that specifically address volatility — standard cannabinoid stability protocols do not automatically demonstrate terpene retention over shelf life.
Formulation
Terpenes may be naturally retained, reintroduced or added as excipients or flavouring components. The source, purity and intended function should be documented. Addition can change irritation, compatibility and exposure.
Where a formulation is designed to preserve a specific terpene ratio, the manufacturing process itself becomes a critical control point, since heat, shear and extended processing time will each drive further volatile loss.
Evidence and the entourage hypothesis
The entourage hypothesis proposes interactions among cannabis constituents, but broad clinical conclusions are not established. Product claims should reflect the level of evidence rather than extrapolate from receptor or animal studies.
Claims invoking the entourage effect should be scoped carefully: the mechanistic and preclinical evidence for terpene-cannabinoid interaction is real, but it does not yet support specific clinical claims for named terpene ratios.
Practical specification strategy
Terpenes may be treated as characterisation markers, stability attributes or controlled formulation components. Not every terpene requires a narrow release limit. The specification should match the product's intended quality profile.
A practical specification strategy treats terpenes as a quality and consistency parameter first, and a marketing differentiator second — the analytical rigour should come before the commercial claim, not after it.
Practical reference table
| Terpene | Typical aroma association | Quality concern |
|---|---|---|
| Myrcene | Earthy/herbal | Volatile loss and oxidation |
| Limonene | Citrus | Oxidation and sensitising products |
| Alpha-pinene | Pine | Volatility and co-elution |
| Linalool | Floral | Oxidative degradation |
| Beta-caryophyllene | Pepper/spice | Method selectivity and stability |
| Humulene | Woody/hoppy | Low-level quantification |
Decision and implementation path
Common implementation mistakes
Common mistakes include choosing a country because cultivation appears attractive without confirming product access; assuming that GMP certification resolves controlled-drug permissions; using broad cannabis terminology where the active substance is not clearly defined; and relying on commercial claims that exceed the available evidence. A second recurring weakness is treating laboratories, logistics providers or cultivators as external to the pharmaceutical quality system. Outsourced work remains part of the regulated supply chain and requires qualification, agreements, performance review and change notification.
Frequently asked questions
Do terpenes determine the medical effect of a product?
They may contribute biologically, but product-specific clinical effects require evidence.
Why do terpene results vary?
Sampling, volatility, oxidation, storage and analytical method all contribute.
Is GC-MS always necessary?
GC-FID can be suitable for routine quantification, while GC-MS provides stronger identification.
Can terpenes be added back after extraction?
Potentially, but source, purity, formulation and regulatory status require control.
Should terpenes be included in stability studies?
Yes when they are relevant to product identity, quality or claims.
Primary references and guidance
- European Pharmacopoeia 2.2.28, Gas Chromatography
- ICH Q2(R2)
- ICH Q14
- EU GMP Part I, Chapter 6
- European Pharmacopoeia, Cannabis flower
- ISO 17025
- Peer-reviewed terpene chemistry and pharmacology literature
Confirm the current effective version and national applicability before operational, medical or regulatory use.